Want to see JP:4888 full AI Analyst Report?

STELLA PHARMA CORPORATION (4888) Price & Analysis

0 Followers

4888 Stock Chart & Stats

¥203.00

-¥14.00(-2.68%)

At close: Jan 08 4:00 PM EST

¥203.00

-¥14.00(-2.68%)

Day’s Range― - ―

52-Week Range¥200.00 - ¥995.00

Previous CloseN/A

Volume163.70K

Average Volume (3M)424.78K

Market Cap

¥14.59B

Enterprise Value¥7.97B

Total Cash (Recent Filing)¥3.80B

Total Debt (Recent Filing)¥899.48M

Price to Earnings (P/E)―

Beta1.04

Next Earnings

Nov 13, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-24.89

Shares Outstanding37,034,100

10 Day Avg. Volume593,010

30 Day Avg. Volume424,776

Financial Highlights & Ratios

PEG Ratio-0.07

Price to Book (P/B)10.64

Price to Sales (P/S)79.85

P/FCF Ratio-74.78

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Manageable LeverageRecent leverage appears manageable and equity remains sizable relative to assets, providing some financial resilience. This capitalization can reduce balance-sheet pressure and preserve flexibility to address operating challenges, although it does not eliminate the effects of ongoing losses.

High Gross MarginsConsistently high gross margins indicate that the company’s offerings retain substantial gross profit after direct costs. If revenue stabilizes, this margin structure could support operating improvement because additional sales may contribute meaningfully toward covering fixed expenses.

2025 Loss ImprovementThe improvement in losses and positive operating and free cash flow during 2025 shows that the business has demonstrated temporary progress toward better financial performance. That record provides evidence of potential operating leverage, even though the improvement was not sustained into 2026.

Bears Say

Sharp Revenue ContractionA roughly 67% revenue decline following a stronger prior year signals highly volatile demand or business performance and weakens planning visibility. Persistent top-line instability can impair operating leverage, make investment decisions harder, and delay a credible path to sustainable profitability.

Deep Structural LossesDeeply negative operating and net margins show that current revenue does not cover the company’s full cost base. The severe 2026 deterioration suggests profitability remains unstable, limiting internally generated funding and making future growth dependent on a material earnings recovery.

Cash-Burning OperationsThe return to negative operating and free cash flow indicates that losses are largely cash-backed and may create periodic funding needs. Continued cash burn can reduce liquidity resilience during weak operating periods and constrain the company’s ability to fund development without external support.

4888 FAQ

What was STELLA PHARMA CORPORATION’s price range in the past 12 months?

STELLA PHARMA CORPORATION lowest stock price was ¥200.00 and its highest was ¥995.00 in the past 12 months.

What is STELLA PHARMA CORPORATION’s market cap?

STELLA PHARMA CORPORATION’s market cap is ¥14.59B.

When is STELLA PHARMA CORPORATION’s upcoming earnings report date?

STELLA PHARMA CORPORATION’s upcoming earnings report date is Nov 13, 2026 which is in 29 days.

How were STELLA PHARMA CORPORATION’s earnings last quarter?

STELLA PHARMA CORPORATION released its earnings results on Aug 13, 2026. The company reported -¥6.55 earnings per share for the quarter.

Is STELLA PHARMA CORPORATION overvalued?

According to Wall Street analysts STELLA PHARMA CORPORATION’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does STELLA PHARMA CORPORATION pay dividends?

STELLA PHARMA CORPORATION does not currently pay dividends.

What is STELLA PHARMA CORPORATION’s EPS estimate?

STELLA PHARMA CORPORATION’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does STELLA PHARMA CORPORATION have?

STELLA PHARMA CORPORATION has 37,034,100 shares outstanding.

What happened to STELLA PHARMA CORPORATION’s price movement after its last earnings report?

STELLA PHARMA CORPORATION reported an EPS of -¥6.55 in its last earnings report. Following the earnings report the stock price went up 0.923%.

Which hedge fund is a major shareholder of STELLA PHARMA CORPORATION?

Currently, no hedge funds are holding shares in JP:4888

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

STELLA PHARMA CORPORATION

Stella Pharma Corporation is a pharmaceutical company that handles the complete process of drug development, from research and manufacturing to distribution. A core area of its specialization is in therapeutic agents for boron neutron capture therapy (BNCT). Their product lineup includes SPM-011, a boron-containing drug designed for BNCT, which is utilized in the treatment of head and neck cancer, recurrent malignant glioma, meningioma, malignant melanoma, and angiosarcoma. Founded in 2007, Stella Pharma Corporation maintains its headquarters in Osaka, Japan.